Raymond James started coverage on shares of Gritstone Oncology (NASDAQ:GRTS) in a research report released on Thursday, MarketBeat.com reports. The brokerage issued an outperform rating and a $20.00 price objective on the stock.
A number of other brokerages have also commented on GRTS. HC Wainwright initiated coverage on shares of Gritstone Oncology in a research report on Thursday, March 7th. They set a buy rating and a $17.00 price objective for the company. BTIG Research upped their price objective on shares of Gritstone Oncology to $31.00 and gave the company a buy rating in a research report on Tuesday, December 11th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has an average rating of Buy and a consensus target price of $22.20.
Shares of GRTS opened at $10.15 on Thursday. Gritstone Oncology has a 52 week low of $9.66 and a 52 week high of $32.90.
About Gritstone Oncology
Gritstone Oncology Inc is engaged in the discovery and development of cancer immunotherapies. The company focuses on developing tumor-specific neo-antigens-based therapies for non-small cell lung cancer. Gritstone Oncology Inc has a strategic collaboration with bluebird bio, Inc The company was incorporated in 2015 and is based in San Francisco, California with operations in Cambridge, Massachusetts.
Recommended Story: What causes a recession?
Receive News & Ratings for Gritstone Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone Oncology and related companies with MarketBeat.com's FREE daily email newsletter.